Viatris PE Ratio 2010-2024 | VTRS
Current and historical p/e ratio for Viatris (VTRS) from 2010 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Viatris PE ratio as of November 20, 2024 is 4.80.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Viatris PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2024-11-19 |
13.05 |
|
0.00 |
| 2024-09-30 |
11.61 |
$-0.74 |
0.00 |
| 2024-06-30 |
10.63 |
$-0.55 |
0.00 |
| 2024-03-31 |
11.94 |
$-0.06 |
0.00 |
| 2023-12-31 |
10.83 |
$0.04 |
270.75 |
| 2023-09-30 |
9.86 |
$1.51 |
6.53 |
| 2023-06-30 |
9.98 |
$1.53 |
6.52 |
| 2023-03-31 |
9.62 |
$1.57 |
6.13 |
| 2022-12-31 |
11.13 |
$1.71 |
6.51 |
| 2022-09-30 |
8.52 |
$0.66 |
12.91 |
| 2022-06-30 |
10.35 |
$0.63 |
16.42 |
| 2022-03-31 |
10.64 |
$0.14 |
76.02 |
| 2021-12-31 |
13.13 |
$-1.26 |
0.00 |
| 2021-09-30 |
13.04 |
$-0.68 |
0.00 |
| 2021-06-30 |
13.65 |
$-0.86 |
0.00 |
| 2020-12-31 |
17.77 |
$-0.59 |
0.00 |
| 2020-09-30 |
14.06 |
$0.52 |
27.04 |
| 2020-06-30 |
15.25 |
$-0.70 |
0.00 |
| 2020-03-31 |
14.14 |
$-0.41 |
0.00 |
| 2019-12-31 |
19.06 |
$-0.78 |
0.00 |
| 2021-03-31 |
13.24 |
$-0.87 |
0.00 |
| 2019-09-30 |
18.75 |
$0.09 |
208.37 |
| 2019-06-30 |
18.05 |
$0.06 |
300.86 |
| 2019-03-31 |
26.87 |
$0.46 |
58.41 |
| 2018-12-31 |
25.98 |
$0.68 |
38.20 |
| 2018-09-30 |
34.70 |
$1.04 |
33.37 |
| 2018-06-30 |
34.26 |
$0.86 |
39.84 |
| 2018-03-31 |
39.03 |
$1.34 |
29.13 |
| 2017-12-31 |
40.11 |
$1.29 |
31.10 |
| 2017-09-30 |
29.74 |
$1.61 |
18.47 |
| 2017-06-30 |
36.81 |
$1.22 |
30.17 |
| 2017-03-31 |
36.97 |
$1.00 |
36.97 |
| 2016-12-31 |
36.17 |
$0.91 |
39.75 |
| 2016-09-30 |
36.14 |
$0.51 |
70.87 |
| 2016-06-30 |
41.00 |
$1.57 |
26.11 |
| 2016-03-31 |
43.94 |
$1.56 |
28.17 |
| 2015-12-31 |
51.26 |
$1.66 |
30.88 |
| 2015-09-30 |
38.18 |
$1.75 |
21.82 |
| 2015-06-30 |
64.34 |
$2.18 |
29.51 |
| 2015-03-31 |
56.27 |
$2.18 |
25.81 |
| 2014-12-31 |
53.44 |
$2.34 |
22.84 |
| 2014-09-30 |
43.13 |
$2.32 |
18.59 |
| 2014-06-30 |
48.88 |
$1.46 |
33.48 |
| 2014-03-31 |
46.30 |
$1.60 |
28.93 |
| 2013-12-31 |
41.15 |
$1.58 |
26.04 |
| 2013-09-30 |
36.19 |
$1.52 |
23.81 |
| 2013-06-30 |
29.42 |
$1.63 |
18.05 |
| 2013-03-31 |
27.45 |
$1.50 |
18.30 |
| 2012-12-31 |
26.03 |
$1.53 |
17.01 |
| 2012-09-30 |
23.11 |
$1.44 |
16.05 |
| 2012-06-30 |
20.26 |
$1.29 |
15.71 |
| 2012-03-31 |
22.23 |
$1.29 |
17.23 |
| 2011-12-31 |
20.35 |
$1.22 |
16.68 |
| 2011-09-30 |
16.11 |
$0.93 |
17.32 |
| 2011-06-30 |
23.39 |
$0.90 |
25.99 |
| 2011-03-31 |
21.48 |
$0.73 |
29.43 |
| 2010-12-31 |
20.03 |
$0.70 |
28.62 |
| 2010-09-30 |
17.83 |
$0.70 |
25.48 |
| 2010-06-30 |
16.16 |
$0.24 |
67.32 |
| 2010-03-31 |
21.53 |
$0.27 |
79.75 |
| 2009-12-31 |
17.47 |
$0.23 |
75.97 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Services |
$15.576B |
$15.427B |
|
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
|
